Log in with your email address username.

×

[Correspondence] Rifampicin in treating S aureus bacteraemia

The deduction that severely ill patients benefit from combination therapy might be tempting, but evidence supporting such an intensified treatment approach is controversial. This was once again shown by Guy E Thwaites and colleagues (Feb 17, p 668),1 who are to be commended for completing the ARREST trial, investigating possible benefits of adjunctive rifampicin in Staphylococcus aureus bacteraemia. The trial findings did not show a significant difference between the rifampicin and placebo groups concerning the composite primary endpoint (bacteriologically confirmed treatment failure or recurrence or all-cause death at week 12).

email